142 related articles for article (PubMed ID: 3006224)
1. Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): Incidence in untreated myeloproliferative disorders.
Bendix-Hansen K
Scand J Haematol; 1986 Jan; 36(1):8-10. PubMed ID: 3006224
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of neutrophil alkaline phosphatase (NAP) activity in untreated myeloproliferative syndromes and in leukaemoid reactions.
Bendix-Hansen K; Bergmann OJ
Scand J Haematol; 1985 Aug; 35(2):219-24. PubMed ID: 4048868
[TBL] [Abstract][Full Text] [Related]
3. Myeloperoxidase-deficient polymorphonuclear leucocytes. (I) Incidence in untreated myeloid leukaemia, lymphoid leukaemia and normal humans.
Bendix-Hansen K; Kaspersen Nielsen H
Scand J Haematol; 1983 May; 30(5):415-9. PubMed ID: 6304866
[TBL] [Abstract][Full Text] [Related]
4. Myeloperoxidase-deficient polymorphonuclear leucocytes. (V): Relation to FAB-classification and neutrophil alkaline phosphatase activity in primary myelodysplastic syndromes.
Bendix-Hansen K; Kerndrup G
Scand J Haematol; 1985 Aug; 35(2):197-200. PubMed ID: 2996123
[TBL] [Abstract][Full Text] [Related]
5. [The activity of the alkaline phosphatase of neutrophils in myeloproliferative diseases].
Vakulenko AD; Shubich MG
Ter Arkh; 1966 Feb; 38(2):66-9. PubMed ID: 5235224
[No Abstract] [Full Text] [Related]
6. Myeloperoxidase deficient polymorphonuclear leucocytes in leukaemia and allied disorders.
Bendix-Hansen K
Dan Med Bull; 1988 Dec; 35(6):501-20. PubMed ID: 2851415
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil 5-nucleotidase reaction in chronic myelogenous leukemia, myelofibrosis with myeloid metaplasia, and polycythemia vera.
Tsavaris NB; Pangalis GA
Ann Hematol; 1998 Jan; 76(1):1-5. PubMed ID: 9486917
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
[TBL] [Abstract][Full Text] [Related]
9. Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders.
Samuelsson J; Forslid J; Hed J; Palmblad J
Br J Haematol; 1994 Jul; 87(3):464-70. PubMed ID: 7993785
[TBL] [Abstract][Full Text] [Related]
10. [An improved method for biochemical measurement of the activity of neutrophil alkaline phosphatase and its application to myeloproliferative disorders].
Tokuda M; Kawanishi K; Irino S
Rinsho Ketsueki; 1991 Aug; 32(8):838-43. PubMed ID: 1942523
[TBL] [Abstract][Full Text] [Related]
11. Muramidase activity in leukemia and myeloproliferative disorders.
Skarin AT; Matsuo Y; Moloney WC
Oncology; 1973; 27(5):406-14. PubMed ID: 4515747
[No Abstract] [Full Text] [Related]
12. Myeloperoxidase-deficient polymorphonuclear leucocytes. Longitudinal study during the preremission--and the remission phase in acute myeloid leukaemia. Comparison to neutrophil alkaline phosphatase (NAP) activity.
Bendix-Hansen K
Blut; 1986 Apr; 52(4):237-42. PubMed ID: 3008894
[TBL] [Abstract][Full Text] [Related]
13. Muramidase in myeloproliferative disorders terminating in acute leukemia.
Skarin AT; Matsuo Y; Moloney WC
Cancer; 1972 May; 29(5):1336-42. PubMed ID: 4502496
[No Abstract] [Full Text] [Related]
14. [MYELOPROLIFERATIVE SYNDROMES].
PIRESWDA F
Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
[No Abstract] [Full Text] [Related]
15. Quantification of JAK2V617F mutation by next-generation sequencing technology.
Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
[No Abstract] [Full Text] [Related]
16. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
17. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
18. Myeloperoxidase-deficient polymorphonuclear leucocytes. (IV): Relation to FAB-classification in acute myeloid leukaemia.
Bendix-Hansen K; Nielsen HK
Scand J Haematol; 1985 Aug; 35(2):174-7. PubMed ID: 2996122
[TBL] [Abstract][Full Text] [Related]
19. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
Shaikh MS; Shaikh MU; Adil SN; Khurshid M; Ahmed ZA
J Ayub Med Coll Abbottabad; 2016; 28(2):293-297. PubMed ID: 28718562
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic and pathogenetic significance of some cytogenetic and cythochemical findings (leukocyte alkaline phosphatase) in systemic hemopathies with myeloproliferative tendencies].
Cacciola E; Giustolisi R
Haematologica; 1970; 55(5):311-32. PubMed ID: 4995787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
